Bausch Health's recent earnings report shows a significant turnaround, driven by strong performance across key business segments.
Bausch Health Companies Inc. (BHC.TO) has reported its second-quarter earnings for 2026, revealing an impressive adjusted earnings per share (EPS) of $1.26, which surpassed analysts' expectations by 24.8%. This marks a notable rebound for the company as it continues to navigate its recovery strategy amid previous financial challenges.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.61B
52W high
$11.97
52W low
$6.10
1W change
+54.40%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 27.4% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-27.4% Upside
Current Price
C$9.65
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
93.6%
Annualized
90-Day Vol
63.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.24 | C$7.41 – C$14.15 |
| 60 trading days | C$10.87 | C$6.88 – C$17.16 |
| 90 trading days | C$11.54 | C$6.59 – C$20.19 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 7 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-07-29 | 1.2600 | 1.0100 | +24.8% |
| 2026-03-31 | 2026-04-29 | 0.7800 | 0.6900 | +13.0% |
| 2025-12-31 | 2026-02-18 | 1.1000 | 1.2100 | -9.1% |
| 2025-09-30 | 2025-10-29 | 1.1600 | 1.0600 | +9.4% |
| 2025-06-30 | 2025-07-30 | 0.9100 | 0.9400 | -3.2% |
| 2025-03-31 | 2025-04-30 | 0.6100 | 0.8500 | -28.2% |
Advertisement
Investor takeaway: With a solid earnings surprise and an upward revision of its revenue guidance, Bausch Health is poised for potential growth. However, investors should remain cautious given the mixed performance indicators and market conditions.
Bausch Health Reports EPS of $1.26, Beating Estimates by 24.8%
The company's revenues also exceeded expectations, coming in at $2.85 billion, a year-over-year increase of 12.7%, indicating a strong recovery trajectory.
Bull case
Bausch's growth in its Salix and Solta Medical segments shows strong demand for its products, especially Xifaxan. The raised full-year revenue guidance reflects management's confidence in continued performance, which could attract investors looking for recovery opportunities.
Bear case
Despite the positive earnings surprise, Bausch Health has underperformed the market this year. The stock's bearish consensus rating and mixed analyst targets might deter risk-averse investors, especially in a volatile market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
